Clinical Vaccine R&D Center, Chonnam National University Medical School, Gwangju, Republic of Korea.
J Microbiol. 2010 Aug;48(4):486-95. doi: 10.1007/s12275-010-0023-z. Epub 2010 Aug 20.
Attenuated bacteria have long been developed as vaccine candidates but can have some disadvantages, such as the potential for damage to immune organs due to insufficient clearance. To minimize these disadvantages, we generated Salmonella enterica serovar Typhimurium mutants SHJ2104 (asd::cm) and HTSaYA (wzy::km, asd::cm). The wzy gene codes for the O-antigen polymerase, which is involved in lipopolysaccharide (LPS) biosynthesis, and asd codes for aspartate beta-semialdehyde dehydrogenase, which participates in cell wall formation. The strains synthesized LPS with a short-chain length, and showed lower cytotoxicity and reduced intracellular proliferation in animal cells compared to wild-type bacteria. After oral infection, the mutants were cleared in immune tissues, including the Peyer's patch, mesenteric lymph node, and spleen, within 5 days. The LD50 of the mutants in Balb/c mice was estimated to be 10(6) higher than wild-type bacteria when administered either via an oral or i.p. route, indicating that the two strains are highly attenuated. To compare the immune response to and protective effects of the mutants against wild-type bacterial infection, we inoculated the mutants into mice via an oral (1x10(10)CFU) or i.p. (1x10(7) CFU) route once or twice at a two week interval. All immune responses, such as serum IgG and secretory IgA levels, cytokine production, and delayed hypersensitivity, were highly induced by two rounds of immunization. HTSaYA and SHJ2104 induced similar immune responses, and mice immunized with HTSaYA or SHJ2104 via an i.p. route were protected against wild-type Salmonella infection even at 100-fold of the LD(50) (5x10(6) CFU). Taken together, these data indicate that HTSaYA and SHJ2104 could be developed as live attenuated Salmonella vaccine candidates.
减毒细菌长期以来一直被开发为疫苗候选物,但可能存在一些缺点,例如由于清除不足而对免疫器官造成潜在损害。为了最大限度地减少这些缺点,我们生成了沙门氏菌血清型 Typhimurium 突变株 SHJ2104(asd::cm)和 HTSaYA(wzy::km,asd::cm)。wzy 基因编码 O-抗原聚合酶,该酶参与脂多糖(LPS)的生物合成,而 asd 编码天冬氨酸 β-半醛脱氢酶,该酶参与细胞壁的形成。这些菌株合成的 LPS 具有短链长,与野生型细菌相比,在动物细胞中表现出更低的细胞毒性和减少的细胞内增殖。经口服感染后,突变株在免疫组织中,包括派尔氏斑、肠系膜淋巴结和脾脏,在 5 天内被清除。突变株在 Balb/c 小鼠中的 LD50 估计比野生型细菌高 10(6)倍,无论是通过口服还是腹腔途径给药,这表明这两种菌株高度减毒。为了比较突变株对野生型细菌感染的免疫反应和保护作用,我们通过口服(1x10(10)CFU)或腹腔(1x10(7)CFU)途径将突变株接种到小鼠中,间隔两周进行一次或两次。所有免疫反应,如血清 IgG 和分泌型 IgA 水平、细胞因子产生和迟发型超敏反应,均通过两轮免疫高度诱导。HTSaYA 和 SHJ2104 诱导相似的免疫反应,通过腹腔途径用 HTSaYA 或 SHJ2104 免疫的小鼠甚至在 LD(50)的 100 倍(5x10(6)CFU)时也能抵抗野生型沙门氏菌感染。总之,这些数据表明 HTSaYA 和 SHJ2104 可作为活减毒沙门氏菌疫苗候选物开发。